|
Cardiac Arrhythmia Pilot Study (CAPS) Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Cardiac Arrhythmia Pilot Study (CAPS) conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Cardiac Arrhythmia Pilot Study (CAPS) Clinical research trials and Cardiac Arrhythmia Pilot Study (CAPS) medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Cardiac Arrhythmia Pilot Study (CAPS). Cardiac Arrhythmia Pilot Study (CAPS) Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Cardiac Arrhythmia Pilot Study (CAPS) clinical trial. Subjects typically recieve the finest healthcare available for their Cardiac Arrhythmia Pilot Study (CAPS) condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cardiac Arrhythmia Pilot Study (CAPS)  Cardiac Arrhythmia Pilot Study (CAPS)
Cardiac Arrhythmia Pilot Study (CAPS)
For Condition: Arrhythmia,Cardiovascular Diseases,Heart Diseases,Ventricular Arrhythmia
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To compare the effectiveness of various drugs and drug combinations in suppressing complex ventricular arrhythmias, and to evaluate their safety.
Details: BACKGROUND: Epidemiologic studies had indicated that complex ventricular premature beats made an independent contribution to risk of sudden death in survivors of a myocardial infarction (MI), and did not appear to be merely a reflection of their association with relatively severe myocardial damage. The potential for reduction in mortality by identification and administration of drugs capable of safely suppressing ventricular arrhythmias was tremendous. In 1982, there was incomplete knowledge regarding which types of ventricular arrhythmias responded to various kinds of drugs. A pilot study of antiarrhythmic agents helped clarify this issue. Numerous antiarrhythmic agents with differing pharmacologic properties and side effects had been shown to suppress ventricular arrhythmias. It had also been postulated that antiarrhythmics might raise an individual's threshold for experiencing ventricular fibrillation. There had been several published reports of large (at least l00 patients), long-term clinical trials of antiarrhythmic agents in post-MI patients. None of these had yielded statistically significant results using mortality as the response variable. This might have been due to incorrect drug selection, inadequate sample size, inappropriate choice of patients, or the lack of impact of arrhythmia treatment on mortality. Due to incomplete knowledge as to which drug(s) and combinations of drugs were most effective, it was considered to be premature to undertake a full scale trial in 1981-1982. However, the public health problem was of sufficient magnitude to warrant a pilot study to learn more about the efficacy and safety of various antiarrhythmic drugs singly or in combination. The protocol planning phase began in October l982. Patient recruitment started in July l983 and ended in the summer of 1985. Each patient was followed for one year. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. A total of 502 patients were randomly assigned to 5 treatment groups consisting of encainide, ethmozine, flecainide, imipramine, and placebo.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Both
Protocol Entry Criteria: Men and women. Patients had acute myocardial infarction and ventricular arrhythmias.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ToshioAkiyama, , University of Rochester
Additional Information:
Study ID Numbers: 23;
Study Start Date: September 1982
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000504
Other Ventricular Arrhythmia Studies:
1. Long QT Syndrome-Population Genetics and Cardiac Studies
2. Multidisciplinary Study of Right Ventricular Dysplasia
3. Prognostic Significance of T Wave Alternans
4. Cardiac Arrhythmia Pilot Study (CAPS)
5. Genetic Determinants of Sudden Cardiac Death
Related Studies:
Other Ventricular Arrhythmia Clinical Trials
Other Clinical Trials
Other Clinical Trials
Cardiac Arrhythmia Pilot Study (CAPS)
|
|
|
|
|
|
|
|
